Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
ATLANTA - Guardian Pharmacy Services, Inc. (NYSE: GRDN), a prominent long-term care (LTC) pharmacy services provider with a market capitalization of $1.37 billion and current trading price of $21.17, has announced the acquisition of Mercury Pharmacy Services, enhancing its presence in the healthcare sector by entering the Washington market. According to InvestingPro analysis, Guardian’s stock has shown mixed performance, with a 32% gain over the past year despite recent market volatility. This move signifies Guardian’s first venture into the state and one of its larger single-pharmacy transactions to date. The acquisition enables Guardian to cater to the increasing demand for LTC pharmacy services in the Pacific Northwest.
Mercury Pharmacy Services, established in 2001, ranks as one of the top LTC pharmacy service providers in the Seattle-Tacoma area, serving a wide customer base across Washington and neighboring regions. Post-acquisition, the current leadership and staff will continue their roles, operating under the Mercury name.
Fred Burke, president and CEO of Guardian Pharmacy Services, emphasized the importance of expanding in areas with a demonstrated need for high-quality LTC pharmacy services. He stated that the acquisition of Mercury Pharmacy Services aligns with their goal to fulfill the growing demand in Washington with a financially robust and high-performing pharmacy.
Guardian’s business model, which will now include Mercury Pharmacy Services, allows local pharmacy teams to concentrate on customer service and the specialized needs of their communities. Meanwhile, Guardian’s Corporate Support Team will manage complex business functions such as data analytics, HR, IT, payer relations, and national sales.
Since its inception in 2004, Guardian Pharmacy Services has grown from a single location to over 50 pharmacies, serving around 7,000 LTC facilities nationwide. This expansion is part of a balanced strategy of organic growth, new startups, and acquisitions, adapting to a dynamic market. The company’s growth strategy appears to be gaining traction, with revenue increasing by 19.54% in the last twelve months to $1.28 billion. InvestingPro data reveals that while currently operating at a loss, analysts expect the company to turn profitable this year.
Guardian Pharmacy Services is recognized for its comprehensive suite of technology-enabled services that support LTC facility residents in adhering to their medication regimens, thereby aiming to reduce care costs and enhance clinical outcomes. As of March 31, 2025, the company’s network of 51 pharmacies serves approximately 189,000 residents across 38 states.
This press release contains forward-looking statements regarding the company’s anticipated growth and service offerings. Guardian Pharmacy Services has stated that it does not plan to update any forward-looking statements, which are subject to risks and uncertainties. The information is based on a press release statement from Guardian Pharmacy Services, Inc. For investors seeking deeper insights, InvestingPro offers comprehensive analysis through its Pro Research Report, available as part of its coverage of 1,400+ US equities, providing detailed metrics, growth projections, and expert analysis to support informed investment decisions.
In other recent news, Guardian Pharmacy Services Inc. reported a notable 20% increase in revenue for the first quarter of 2025, reaching $329.3 million. The company’s earnings per share for the quarter were $0.15. Guardian Pharmacy also provided optimistic guidance for the year, expecting full-year revenue to be in the upper half of its projected range between $1.33 billion and $1.35 billion. Additionally, Guardian Pharmacy announced the acquisition of Senior Care Pharmacy in Wichita, Kansas, expanding its operations within the state. This move is part of Guardian’s ongoing strategy to enhance its service capabilities through acquisitions. In another development, Guardian Pharmacy entered into stock purchase agreements to repurchase up to 1,457,365 shares of its Class A common stock, funded by a concurrent public offering. Meanwhile, the company announced a public offering of 7.5 million shares of Class A common stock, with Raymond James leading the offering. These recent developments reflect Guardian Pharmacy’s strategic focus on growth and financial restructuring.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.